1. Home
  2. MRM vs KZIA Comparison

MRM vs KZIA Comparison

Compare MRM & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRM
  • KZIA
  • Stock Information
  • Founded
  • MRM 2000
  • KZIA 1994
  • Country
  • MRM Japan
  • KZIA Australia
  • Employees
  • MRM N/A
  • KZIA N/A
  • Industry
  • MRM Other Consumer Services
  • KZIA Biotechnology: Pharmaceutical Preparations
  • Sector
  • MRM Consumer Discretionary
  • KZIA Health Care
  • Exchange
  • MRM Nasdaq
  • KZIA Nasdaq
  • Market Cap
  • MRM 5.9M
  • KZIA 5.1M
  • IPO Year
  • MRM 2020
  • KZIA 1999
  • Fundamental
  • Price
  • MRM $1.45
  • KZIA $6.51
  • Analyst Decision
  • MRM
  • KZIA Strong Buy
  • Analyst Count
  • MRM 0
  • KZIA 2
  • Target Price
  • MRM N/A
  • KZIA $57.50
  • AVG Volume (30 Days)
  • MRM 36.9K
  • KZIA 2.6M
  • Earning Date
  • MRM 05-20-2025
  • KZIA 07-07-2025
  • Dividend Yield
  • MRM N/A
  • KZIA N/A
  • EPS Growth
  • MRM 27.65
  • KZIA N/A
  • EPS
  • MRM 0.18
  • KZIA N/A
  • Revenue
  • MRM $52,786,758.00
  • KZIA $1,549,158.00
  • Revenue This Year
  • MRM N/A
  • KZIA N/A
  • Revenue Next Year
  • MRM N/A
  • KZIA N/A
  • P/E Ratio
  • MRM $7.83
  • KZIA N/A
  • Revenue Growth
  • MRM 21.55
  • KZIA 248983.08
  • 52 Week Low
  • MRM $0.34
  • KZIA $2.86
  • 52 Week High
  • MRM $8.39
  • KZIA $79.00
  • Technical
  • Relative Strength Index (RSI)
  • MRM 50.91
  • KZIA 49.53
  • Support Level
  • MRM $1.33
  • KZIA $6.00
  • Resistance Level
  • MRM $1.50
  • KZIA $9.60
  • Average True Range (ATR)
  • MRM 0.09
  • KZIA 1.16
  • MACD
  • MRM -0.04
  • KZIA -0.32
  • Stochastic Oscillator
  • MRM 24.32
  • KZIA 15.84

About MRM MEDIROM Healthcare Technologies Inc.

MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Share on Social Networks: